IDMC reviews data from Nanobiotix’s NBTXR3 Phase I study on advanced soft tissue sarcoma

Nanobiotix (Euronext: NANO / ISIN: FR0011341205), announced today that the Independent Data Monitoring Committee (IDMC) has reviewed the data of the first 6 patients treated in the phase I Study with the lead product NBTXR3 for the treatment of advanced Soft Tissue Sarcoma of the extremity. Based on the review of the safety data, the IDMC has unanimously recommended continuing the enrollment in the study according to the protocol. This trial is realized in the Institut Gustave Roussy, France.

"This milestone is crucial for NANOBIOTIX" says Laurent Levy, CEO and co-founder of Nanobiotix. "It is in accordance with our expectations concerning our NanoXray products' risk profile. After our successful IPO, we are happy to deliver this first milestone to all our investors and subscribers who have had confidence in the company. We intend to continue to deliver with our breakthrough technology to bring those products to patients rapidly and efficiently. This initial step is "derisking" our approach and gives us confidence to expend the clinical development to different indications."

The IDMC consists of 3 independent members and has the responsibility of ensuring the safety of all patients enrolled in the study, the quality of the data collected and the continued scientific validity of the study design. The IDMC has reviewed the data of the first group of patients, focusing on patient's safety and tumor surgery feasibility.

The clinical trial evaluates the following endpoints:

• Primary endpoints
  • Feasibility of the injection of NBTXR3 and its activation by radiotherapy in small and big tumors
  • Safety profile of NBTXR3 and its activation by radiotherapy
• Secondary endpoints
  • Tumor response to NBTXR3 activated by radiotherapy, in terms of cancer cell killing
  • Tumor downsizing and carcinologic surgery feasibility with NBTXR3 activated by radiotherapy (medical imaging)
  • Kinetic profile of NBTXR3 in the body

In this first group of patients, all the primary endpoints were reached, NBTXR3 demonstrated good safety and surgery was feasible with limb preservation in all patients.

The IDMC interim safety analysis found no evidence of local or general toxicity and accordingly the study is continuing. Based on their analysis, the committee has recommended starting the second group of patients without protocol amendments.

"The safety data from the first stage of the Phase I study met our expectations and confirms the positive safety data from our non-clinical studies results" said Dr. Elsa Borghi, Nanobiotix Medical Director. "A first milestone has been achieved in Nanobiotix' mission to address the medical need in patients with advanced tumors at high risk. We look forward to the next steps for NBTXR3 and remain confident in its potential to provide a new and important therapeutic option for patients with cancers."

The trial is a prospective, open-label, dose-escalation and single arm study. NBTXR3 is administered to the patients by a single intra-tumor injection, followed by standard radiotherapy as pre-operative treatment. This pre-surgical treatment aims at shrinking the tumor or rendering possible the extraction of the whole malignant tissue, i.e. all cancer cells are resected. After completion of the regular treatment procedure, the patients will undergo the soft tissue sarcoma surgery. The primary tumor tissue will then be available for the evaluation of the cancer cell killing.

Patients' candidates for this new modality of treatment are selected by the Sarcomas and Mesenchymal Tumors Committee of the Institut Gustave Roussy, which represents a highly specialized medical group for sarcoma care for more than 500 newly diagnosed patients per year.